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ABBREVIATIONS
IRR Incidence rate ratio
MAD Mood affective disorder
AIM To determine if pain is associated with 12-month incidence of mood affective disorders
(MAD) in adults with cerebral palsy (CP).
METHOD Data from Optum Clinformatics Data Mart (2013–2016) were used for this
retrospective cohort study. Diagnostic codes were used to identify adults (≥18y) with CP,
incident cases of MAD, and covariates (other neurodevelopmental conditions, sleep disorders,
arthritis). Pain (any type, location) was identified between 1st October 2014 and 30th September
2015. The pain group was divided into new or consistent pain if they had a history of pain (i.e.
consistent) in the 12 months before their first pain claim date. Crude incidence rates of MAD
(expressed per 100 person-years) were estimated. Cox regression was used to estimate hazard
ratio (95% confidence interval [CI]) of MAD after adjusting for covariates.
RESULTS Adults that had new pain (n=859; incidence rate=15.5) or consistent pain (n=1303;
incidence rate=17.9) had greater crude incidence rate of MAD compared to adults without
pain (n=3726; incidence rate=5.9). The elevated rate of MAD remained after adjusting for
covariates, for new pain (hazard ratio=2.4; 95% CI=1.9–3.0) and consistent pain (hazard
ratio=2.1; 95% CI=1.7–2.7).
INTERPRETATION Pain is associated with greater incidence of MAD in adults with CP. This
association remained after accounting for potential confounding factors.
The wide array of complications associated with cerebral
palsy (CP) increases risk for developing a variety of physio-
logical changes,1,2 including mental health disorders.3
Given that CP is a chronic condition with evidence of
accelerated decline in health and function throughout the
lifespan,4–6 the risk of mental health disorders is likely
increased throughout adulthood.7 Indeed, emerging evi-
dence has started to shed light on mental health-related
risks for individuals with CP.3,8–11 In a nationwide study in
the US, adults with CP were found to have a higher preva-
lence of a variety of mental health disorders compared to
adults without CP, with mood affective disorder (MAD)
the most prevalent mental health disorder for adults with
CP.9 In a nationwide study from the UK, the incidence of
MAD was higher for adults with versus without CP.8 This
is concerning because mental health disorders, and particu-
larly MAD, are implicated in the pathogenesis of unhealthy
aging, and are therefore of great public health concern.12
While attention towards understanding the burden of
MAD for adults with CP is growing, there is a dearth of
evidence identifying longitudinal risk factors for predicting
MAD. Recent cross-sectional work suggest a clustering of
many commonly reported clinical factors with MAD
among individuals with CP, including pain, sleep disorders,
and arthritis, among other factors (e.g. fatigue, loneli-
ness).3,10,13–16 The mechanisms linking these factors are
complex and dynamic, and may be driven by unique attri-
butes of the individual, cognitive ability, health history, or
a shared neurobiological etiology. Further, the temporal
sequence of developing these clinical factors can differ
across clinical populations,17,18 making clinical diagnosis,
prevention, and treatment of MAD challenging.
To date, the temporal sequence of pain, sleep disorders,
arthritis, and MAD is unknown for adults with CP. In
other populations, there is mixed evidence of bidirectional
causal relations between pain and MAD, with evidence to
suggest that medical (or biological), psychological, and
social factors mediate the association as well as drive the
causal direction.19,20 Limited longitudinal studies of the
effects of pain treatment suggest positive effects of pain
reduction on MAD symptoms.21 In the population with
CP, the association between pain and MAD may be influ-
enced by the underlying mechanism causing CP and
comorbid neurodevelopmental conditions, including
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intellectual disabilities, autism spectrum disorders, and epi-
lepsy, each associated with mental health disorders.22–24
The objective of this study was to determine the associa-
tion between pain and 12-month incidence of MAD among
adults with CP. We hypothesized that pain would be asso-
ciated with higher 12-month incidence of MAD, even after




Data from 2013 to 2016 were extracted from the Optum
Clinformatics Data Mart Database (OptumInsightTM,
Eden Prairie, MN, USA), a US nationwide deidentified
single private payer administrative claims database.25 This
database contains data from beneficiaries who have either
commercial or Medicare Advantage health plans, and
includes all service utilization (e.g. inpatient, outpatient)
throughout their enrolment on the insurance plan. Medi-
care beneficiaries can opt to enrol in a private Medicare
Advantage health plan. These plans can offer additional
coverage not available in the public Medicare program
(e.g. vision, hearing, dental). To be enroled in a private
payer health plan, beneficiaries of any age, income, or dis-
ability status either pay for coverage or are covered
through their employer or parents up to the age of 26
years. To preserve patient identity, researchers leveraging
this database are allowed either the Date of Death or
Socioeconomic Status table. The current investigation was
developed under a larger project in which the Date of
Death table was obtained. Therefore, some information
regarding socioeconomic status (i.e. income, education)
were not available. Since data are deidentified, the Univer-
sity Institutional Review Board approved this study as non-
regulated.
Sample selection
Medical conditions were identified using the International
Classification of Diseases, 9th and 10th Revisions (ICD-9
and ICD-10), Clinical Modification codes to account for
the shift in reporting codes on 1st October 2015, and are
presented in Table 1.
The period of 1st October 2014 to 30th September
2015 was initially used to identify eligible participants:
adults 18 years of age or older with CP with at least one
service utilization (to limit detection bias among persons
who were not seen by a physician). We defined CP by at
least one claim for any CP diagnosis.25 Data regarding
severity of CP are not available in claims and more than
70% had ‘other’ or ‘unspecified’ CP, thereby preventing
stratification of the sample by clinical CP subtypes.
The exposure variable was pain, including, but not lim-
ited to, central pain syndrome, chronic pain conditions,
dorsalgia, and pain in joints. We defined pain in three
steps. First, we identified the first claim for pain during
the period of 1st October 2014 and 30th September
2015. Second, individuals had to have at least one more
claim for pain on a subsequent day within 12 months
after their first pain claim date in step 1, to rule out ini-
tial claims that may have been for screening. Third, we
categorized our sample based on ‘new’ or ‘consistent’ pain
using a look-back period of 12 months. Therefore, fur-
ther eligibility criteria involved continuous enrolment in a
health plan and at least one of any service utilization
types (e.g. inpatient) in the 12 months before their first
pain claim date in step 1: new pain was defined as not
having any claim for pain within 12 months before the
first pain claim date in step 1; consistent pain was defined
as having at least one claim for pain (any type or loca-
tion) within 12 months before the first pain claim date in
step 1. We grouped all pain conditions into a single
dichotomous variable (i.e. yes/no) because the majority of
diagnosed pain conditions are presumed to come from
physicians that have little knowledge on how to ade-
quately treat and/or monitor health for their adult
patients with CP. Therefore, the accuracy of diagnosing
pain (e.g. etiology, chronicity) in this database may be
lower than the accuracy of identifying the presence/ab-
sence of any type of pain. We designated ‘new’ and ‘con-
sistent’ pain as a proxy for new onset versus chronic of
any of the included pain conditions.
The comparison group in this study consisted of adults
with CP that did not have any claims for pain between 1st
October 2014 and 30th September 2015, and that also had
at least one service utilization in the look-back period. The
start date of follow-up was the date of the first claim for
pain or a randomly assigned date for adults without pain
by using a uniform distribution to randomly assign a date
during the individual’s enrolment period.
Outcome measure
The outcome event was the occurrence of incident MAD
up to 12 months after the start date of follow-up, defined
by at least one claim.9 Individuals were excluded if they
had at least one claim for MAD in their 12-month look-
back period.
Covariates
Sociodemographic covariates included age, sex, ethnic
group, and US region. Neurodevelopmental conditions
included intellectual disabilities, autism spectrum disor-
ders, and epilepsy. Baseline sleep disorders and arthritis
and other inflammatory polyarthropathies (hereafter
referred to as ‘arthritis’) were identified in the look-back
period. Healthcare utilization was determined as the num-
ber of all service visits (e.g. inpatient) during the look-
back period.
What this paper adds
• Pain was associated with higher 12-month incidence of mood affective dis-
orders (MAD).
• The 12-month MAD incidence was similar between new and consistent pain
groups.
• The MAD incidence remained higher adjusting for neurodevelopmental
comorbidities, sleep disorders, and arthritis.
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Statistical analysis
Crude incidence rates of MAD were estimated as the num-
ber of outcome events divided by the amount of person-
years, expressed per 100/year. Crude incidence rate ratios
(IRRs) and 95 per cent CIs were estimated using the group
without pain as the reference. Individuals were right cen-
sored at death, loss to follow-up, or end of study period
(12mo after start date of follow-up).
Cox proportional hazard regression models were fitted
to adjust for covariates when comparing incidence rate, by
estimating hazard ratios (95% CI) of MAD incidence,
comparing each exposure group with the reference group.
Three sets of covariates were used to explain the difference
in crude rates between groups: model 1 – age (continuous),
sex, US region, and healthcare utilization (quintiles); model
2 – model 1 covariates plus neurodevelopmental condi-
tions; and model 3 – model 2 covariates plus baseline sleep
disorders and arthritis. Possible interactions between expo-
sure status and age or sex were assessed by conducting sep-
arate analyses for age or sex strata and including product
terms in the Cox models. Proportional hazards assumption
was visually inspected and was met.
Sensitivity analysis
Ethnic group was not adjusted for in the Cox regression
models to limit potential bias because of missing ethnic
group data. We conducted two sensitivity analyses to
assess for possible confounding and selection bias in the
main analysis. Sensitivity analysis #1 was a complete case
analysis that did not adjust for ethnic group; sensitivity
analysis #2 was a complete case analysis that adjusted for
ethnic group. Results were compared from sensitivity
analyses #1 and #2 to assess possible confounding by eth-
nic group. Results were also compared from sensitivity
analysis #1 and the main analysis to assess for possible
selection bias attributable to exclusion of adults without
ethnic group data.
We excluded individuals from the main analysis that
had one claim for pain between 1st October 2014 and
30th September 2015 and without a subsequent claim for
pain 12 months after that met other inclusion criteria
(n=349). We conducted a sensitivity analysis using the
procedures described above after adding these individuals
to the respective pain group, to assess for possible selec-
tion bias.
Table 1: Diagnostic codes for all medical conditions using the International Classification of Diseases, 9th or 10th revision (ICD-9/ICD-10), Clinical
Modification system
Medical conditions ICD-9 family or individuals codes
ICD-10 family or individuals
codes
Neurodevelopmental conditions
Cerebral palsy 333.71, 343 family G80 family
Intellectual disabilities 317–19 families, 758.0–2, 758.31 F70–73 families, F78, F79
Autism spectrum disorders 299.00, 299.01, 299.10, 299.11, 299.80,
299.81, 299.90, 299.91
F84.0, F84.3, F84.5, F84.8, F84.9
Epilepsy 345 family G40 family
Pain
Central pain syndrome; other chronic pain; chronic pain
syndrome; abdominal pain; dorsalgia, including
panniculitis affecting regions of the neck and back,
radiculopathy, cervicalgia, sciatica, lumbago with sciatica,
low back pain, pain in thoracic spine, other or unspecified
dorsalgia; pain in joint, including shoulder, elbow, wrist,
hand, hip, knee, ankle/foot; other or unspecified pain
338.0, 338.29, 338.4, 719.4 family, 724.1
–5, 729.5, 780.96, 789.0 family
G89.0, G89.29, G89.4, M54
family, M25.5 family, R10
family, R52 family
Mood (affective) disorders
Manic episode; bipolar disorder; major depressive
disorder, single episode and recurrent; persistent mood
(affective) disorders; unspecified mood (affective)
disorders
296 family, 300.4, 301.12, 311 family F30–34 families, F39
Sleep disorders
Insomnia; hypersomnia; circadian rhythm sleep disorders;
sleep apnea; narcolepsy and cataplexy; parasomnia; sleep
related movement disorders; other or unspecified sleep
disorders; sleep disorders not due to a substance or
known physiological condition, including insomnia,
hypersomnia, sleepwalking, sleep terrors, nightmare
disorder, other or unspecified sleep disorder
307.4 family, 327.0–5 families, 347.00,




Rheumatoid arthritis and other inflammatory
polyarthropathies; osteoarthritis and allied disorders
714 family, 715 family a
aICD-9 version was used only.
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Because of the observational design and lack of medica-
tion information (e.g. anti-epileptic drugs, pain medica-
tion), which is a limitation to the current study, results are
subject to bias from unmeasured confounding. We esti-
mated the extent of unmeasured confounding by comput-
ing e-values, which measures the minimum strength of
association needed to explain a specific exposure-outcome
association, conditional on the set of covariates.26
Analyses were performed using SAS version 9.4 (SAS
Institute, Cary, NC, USA).
RESULTS
Baseline descriptive characteristics of adults without pain
(n=3726), new pain (n=859), and consistent pain (n=1303)
are presented in Table 2.
Incidence rate of MAD
The crude incidence rate was 5.86 for adults without pain,
15.52 for new pain, and 17.92 for consistent pain (Table 3).
Compared to adults without pain, the crude IRR was ele-
vated for adults with new pain (IRR=2.65; 95% CI=2.10–
3.34) and consistent pain (IRR=3.06; 95% CI=2.51–3.73).
Compared to adults with consistent pain, the crude IRR
was similar for adults with new pain (IRR=0.87; 95%
CI=0.69–1.09; data not shown).
Cox regression analysis of MAD
Compared to adults without pain, the hazard ratio (95%
CI) adjusting for demographic variables and healthcare uti-
lization (model 1) was 2.35 (1.86–2.97) for adults with new
pain and 2.22 (1.79–2.76) for adults with consistent pain
(Table 3). The hazard ratios were not largely affected
when further adjusting for comorbid neurodevelopmental
conditions (model 2). After further adjustment for sleep
disorders and arthritis (model 3), the hazard ratio was
unaffected compared to model 1 for adults with new pain
(hazard ratio=2.35; 95% CI=1.86–2.97) and decreased
slightly from model 1 for adults with consistent pain, but
remained elevated (hazard ratio=2.13; 95% CI=1.71–2.67).
The adjusted rate of MAD was not different for adults
with new versus consistent pain when adjusting for covari-
ates in model 1 (hazard ratio=1.06; 95% CI=0.83–1.35),
model 2 (hazard ratio=1.07; 95% CI=0.84–1.37), and
model 3 (hazard ratio=1.10; 95% CI=0.86–1.41; data not
shown).
Sensitivity analysis
For individuals with complete data on ethnic group
(n=5075), the MAD cases, incidence rate, and IRR (refer-
ence: without pain) were 161 and 5.63 for adults without
pain, 102 and 15.58 for new pain (IRR=2.77; 95%
CI=2.16–3.55), and 160 and 17.67 for consistent pain
(IRR=3.14; 95% CI=2.52–3.91). Adjusted hazard ratios of
MAD are presented in Table 4. Crude incidence rate and
IRR were similar to the main analysis. A comparison of
hazard ratio estimates from sensitivity analysis #1 and #2
show similar results, suggesting that ethnic group is not a
confounder in the main analysis. A comparison of hazard
ratio estimates from sensitivity analysis #1 and the main
analysis show similar results, providing no evidence to sug-
gest selection bias.
The results of the sensitivity analysis that included indi-
viduals with at least one claim for pain (n=1080 new pain;
n=1431 consistent pain) were in accordance with the main
analysis for the new pain group (incidence rate=13.93;
IRR=2.38, 95% CI=1.90–2.97; model 3 hazard ratio=2.13,
95% CI=1.70–2.66) and consistent pain group (incidence
rate=17.02; IRR=2.91, 95% CI=2.39–3.54; model 3 hazard
ratio=2.00, 95% CI=1.61–2.48), providing no evidence to
suggest selection bias.
The e-value (lower 95% CI) was 4.13 (3.12) for new
pain versus no pain and 3.68 (2.81) for consistent pain ver-
sus no pain. Given the large e-values, it appears unlikely
that unmeasured confounding or lack of medication infor-
mation largely biased effect estimates for the exposure
variables.
Table 2: Baseline descriptive characteristics of adults with cerebral pal-









44:9 (19:4) 52:8 (19:0) 56:8 (17:2)
18–40y 45.5 (1697) 29.3 (252) 18.6 (242)
41–64y 35.1 (1309) 39.6 (340) 47.4 (618)
≥65y 19.3 (720) 31.1 (267) 34 (443)
Sex
Female 44.7 (1667) 50.4 (433) 50.3 (655)
Male 55.3 (2059) 49.6 (426) 49.7 (648)
Ethnic group
White 64.0 (2385) 67.5 (580) 61.2 (798)
Black 9.2 (344) 10.5 (90) 11.4 (148)
Hispanic 10.0 (372) 8.4 (72) 8.4 (110)
Asian 3.6 (135) 2.3 (20) 1.6 (21)
Unknown/
missing
13.2 (490) 11.3 (97) 17.3 (226)
US region
West 27.7 (1031) 28.1 (241) 25.1 (327)
Midwest 24.0 (896) 23.4 (201) 23.4 (305)
South 38.7 (1441) 37.1 (319) 37.2 (485)
Northeast 9.2 (342) 10.9 (94) 14.0 (183)
Unknown/
missing
0.4 (16) 0.5 (4) 0.2 (3)
Intellectual
disabilities




4.6 (173) 2.4 (21) 1.6 (21)
Epilepsy 29.1 (1083) 22.4 (192) 21.6 (281)
Sleep disorders 4.5 (169) 6.1 (52) 10.1 (131)
Arthritis 4.1 (152) 5.7 (49) 20.3 (265)
Healthcare utilization (# of visits)
Median (IQR) 8 (4–19) 11 (5–22) 24 (13–42)
Quintiles
1–4 29.3 (1093) 22.2 (191) 3.6 (47)
>4–8 22.7 (846) 17.1 (147) 10.0 (130)
>8–15 18.6 (694) 24.2 (208) 17.4 (227)
>15–31 15.2 (566) 20.0 (172) 30.5 (397)
>31 14.1 (527) 16.4 (141) 38.5 (502)
Data are % (n) unless otherwise stated. SD, standard deviation;
IQR, interquartile range.
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DISCUSSION
The main finding of this study is that pain, whether new
onset or consistent, was associated with greater 12-month
incidence of MAD among adults with CP, which was lar-
gely unaffected by comorbid neurodevelopmental condi-
tions, sleep disorders, and arthritis. Mental health
disorders, and particularly MAD, are a primary driver of
the burden of disease for adults12 and can be prevented or
treated if adequate clinical knowledge is established leading
to detection and response. Knowing that pain increases risk
of MAD suggests the need for improved screening strate-
gies and opportunities for intervention to mitigate risk of
both pain and MAD specific to the heterogeneous and
medically complex nature of CP.
In the current study, the prevalence of pain was
approximately 37%, consistent with the range of 33% to
75% previously reported for individuals with CP.10,27
The 12-month incidence of MAD for the entire CP
cohort was approximately 9%, which is lower than the
18% for depression previously reported.8 However, the
study by Smith et al.8 examined incidence over a 28-year
period. In the current study, there were considerable dif-
ferences in age and healthcare utilization. We therefore
used Cox regression to adjust for age, sex, US region,
and healthcare utilization. The adjusted hazard ratios
were more than twofold higher compared to adults with-
out pain. Further adjustment for comorbid neurodevelop-
mental conditions, sleep disorders, and arthritis, which
are all implicated in the pathogenesis of pain and MAD,
had little-to-no impact on hazard ratios for both pain
groups. After adjusting for all covariates, pain was associ-
ated with a 2.1- to 2.4-fold higher rate of MAD
compared to no pain among adults with CP, with no dif-
ference between the pain groups.
The link between pain, sleep disorders, arthritis, and
MAD is complex, especially for CP, and may be affected
by patient (e.g. comorbidities, resilience, loneliness) and
environmental (e.g. socioeconomic status, adverse events)
characteristics. This study was designed to investigate the
pathway of pain to incident MAD, and we found a robust
association; however, this study does not rule out the pos-
sibility that sleep disorders or other factors may be
involved early in the pathogenic pathway leading to pain
(or pain exacerbation) and/or MAD for a different sector
of the CP population, or that MAD leads to these factors.
Studies in different clinical populations suggest unique
pathways where pain impedes sleep, with a subsequent
effect on depressive symptoms.17 On the other hand, sleep
disorders may contribute to exacerbating pain and, conse-
quently, heighten depressive symptoms.28 Also, depressive
symptoms have been suggested as a mediator of the sleep-
pain association.18 Further longitudinal investigation of the
temporal sequence of pain, sleep disorders, arthritis, and
MAD will be essential in establishing causal arguments and
developing an understanding of the possible mechanisms
that link these factors among adults with CP.
There are a number of limitations of this study. First,
data were from a private payer claims database, which
likely reflects the higher-functioning segment of the CP
population. This speculation is based on differences in
enrolment criteria between private and public insurance
types, medical needs of individuals with CP based on
insurance coverage, and prevalent chronic diseases for
adults with pediatric-onset disabilities (higher among
Table 3: Crude incidence rate and incidence rate ratio and adjusted hazard ratio of mood affective disorders (MAD) among adults with cerebral palsy
by pain status
MAD cases Crude IR Crude IRR Model 1 Model 2 Model 3
n n per 100/years IRR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Without pain 193 5.86 Reference Reference Reference Reference
New pain 114 15.52 2.65 (2.10–3.34) 2.35 (1.86–2.97) 2.34 (1.85–2.96) 2.35 (1.86–2.97)
Consistent pain 196 17.92 3.06 (2.51–3.73) 2.22 (1.79–2.76) 2.18 (1.75–2.72) 2.13 (1.71–2.67)
IR incidence rate; IRR incidence rate ratio; Model 1 age sex US region healthcare utilization; Model 2 model 1 variables and intellectual dis-
abilities autism spectrum disorders epilepsy; Model 3 model 2 variables and baseline sleep disorders baseline arthritis; HR hazard ratio; CI
confidence interval.
Table 4: Adjusted hazard ratio and 95% confidence interval of mood affective disorders among adults with cerebral palsy by pain status with complete
data on ethnic group (n=5075)
Model 1
Model 1 + ethnic
group Model 2
Model 2 + ethnic
group Model 3
Model 3 + ethnic
group
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)





2.21 (1.74–2.81) 2.18 (1.71–
2.78)
2.24 (1.76–2.84) 2.19 (1.72–
2.78)
2.16 (1.69–2.75)
New pain 2.42 (1.88–
3.11)
2.40 (1.87–3.09) 2.39 (1.86–
3.08)
2.41 (1.87–3.10) 2.39 (1.86–
3.07)
2.38 (1.85–3.07)
HR hazard ratio; CI confidence interval; Model 1 age sex US region healthcare utilization; Model 2 model 1 variables and intellectual dis-
abilities autism spectrum disorders epilepsy; Model 3 model 2 variables and baseline sleep disorders baseline arthritis.
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publicly vs privately insured), including CP.25,29 It is
important to note that while the prevalence estimates of
the exposure and outcome may reflect the higher-function-
ing segment of the CP population, it is plausible that the
direction, and even the strength, of the exposure-outcome
association observed in this study is representative of what
occurs in the general CP population. Nevertheless, study
conclusions should be considered within the scope of this
particular population of privately insured adults with CP.
Second, in order to be identified as having pain in claims
data, the individual must be aware of their pain levels and
communicate this to their healthcare provider. Some indi-
viduals with more severe forms of CP, cognitive or com-
munication impairments, or who have become desensitized
to their chronic pain condition may not have communi-
cated their pain. Same holds true for MAD, which often
goes unrecognized in CP.
Third, we did not stratify the pain group by pain type.
Pain can be driven by peripheral or central mechanisms, or a
combination of both. Historically, pain is not well assessed
or characterized for the CP population. Pain may be
assumed to be more peripherally driven from muscles and
joints because of altered mechanical loading patterns, a his-
tory of orthopedic abnormalities and surgical interventions,
or higher prevalence of arthritis.30 Therefore, a medical pro-
fessional with little experience treating adults with CP may
be more likely to incorrectly diagnose pain, and thus be
incorrectly reflected in claims data. In addition, consistent
pain was defined as a claim for any pain condition, not nec-
essarily the same pain condition, in the 12 months before the
first pain claim. Future studies are warranted to identify
which pain conditions are associated with MAD incidence.
Fourth, although we were following traditional claims-
based methods, the relatively short time period may have
missed those that had MAD before pain.
Fifth, MAD based on ICD codes instead of the Diagnos-
tic and Statistical Manual of Mental Disorders may either
underscore or overrate MAD.
Sixth, we did not adjust for other mental health disor-
ders (e.g. anxiety) or substance abuse. Future studies are
needed to investigate how these conditions factor into the
association between pain and MAD, which could assist in
clinical monitoring and treatment of mental health disor-
ders for adults with CP.
In conclusion, pain is associated with greater 12-month
incidence of MAD among privately insured adults with
CP. The pain-MAD association was largely unaffected by
the presence of neurodevelopmental conditions, sleep dis-
orders, and arthritis. Future studies are needed to deter-
mine whether effective pain management reduces the risk
of onset of MAD.
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